Psychopharmacology of autism spectrum disorders

被引:3
作者
Poustka, L. [1 ]
Banaschewski, T. [1 ]
Poustka, F. [2 ]
机构
[1] Zent Inst Seel Gesundheit, Klin Psychiat & Psychotherapie Kindes & Jugendalt, D-68159 Mannheim, Germany
[2] Privatpraxis Facharzt Zentrum, Frankfurt, Germany
来源
NERVENARZT | 2011年 / 82卷 / 05期
关键词
Autism; Comorbidity; Aggression; Psychopharmacology; Atypical antipsychotic agents; PERVASIVE DEVELOPMENTAL DISORDERS; PLACEBO-CONTROLLED CROSSOVER; CONTROLLED-RELEASE MELATONIN; DOUBLE-BLIND; CONTROLLED-TRIAL; PHARMACOLOGICAL-TREATMENT; REPETITIVE BEHAVIORS; CHILDREN; RISPERIDONE; OXYTOCIN;
D O I
10.1007/s00115-010-3238-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Autism spectrum disorders (ASD) are persistent, heterogeneous conditions that display many comorbid problems. Especially maladaptive behaviours like increased irritability, aggression, impulsivity and self-injurious behaviours are perceived as enormously stressful and can interfere with interventions targeting social and communication deficits. Medication treatments focussing on troubling comorbid problems in ASD can be fundamentally ameliorative, although core features of the disorder itself cannot be sufficiently treated. While atypical antipsychotics and stimulant medication have been proven to be effective in large multisite networks of ASD, serotonin reuptake inhibitors are of limited efficacy. Novel pharmacotherapies to improve social impairment are in the early stages of research.
引用
收藏
页码:582 / +
页数:6
相关论文
共 41 条
[1]  
Aman M. G., 2009, J AM ACAD CHILD ADOL
[2]   Cognitive effects of risperidone in children with autism and irritable behavior [J].
Aman, Michael G. ;
Hollway, Jill A. ;
McDougle, Christopher J. ;
Scahill, Lawrence ;
Tierney, Elaine ;
McCracken, James T. ;
Arnold, L. Eugene ;
Vitiello, Benedetto ;
Ritz, Louise ;
Gavaletz, Allison ;
Cronin, Pegeen ;
Swiezy, Naomi ;
Wheeler, Courtney ;
Koenig, Kathleen ;
Ghuman, Jaswinder K. ;
Pose, David J. .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2008, 18 (03) :227-236
[3]   Melatonin for insomnia in children with autism spectrum disorders [J].
Andersen, Ivy M. ;
Kaczmarska, JoAnna ;
McGrevv, Susan G. ;
Malow, Beth A. .
JOURNAL OF CHILD NEUROLOGY, 2008, 23 (05) :482-485
[4]  
[Anonymous], MED GENETIK
[5]   Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial [J].
Arnold, L. Eugene ;
Aman, Michael G. ;
Cook, Amelia M. ;
Witwer, Andrea N. ;
Hall, Kristy L. ;
Thompson, Susan ;
Ramadan, Yaser .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2006, 45 (10) :1196-1205
[6]   Parent-defined target symptoms respond to risperidone in RUPP autism study: Customer approach to clinical trials [J].
Arnold, LE ;
Vitiello, B ;
McDougle, C ;
Scahill, L ;
Shah, B ;
Gonzalez, NM ;
Chuang, S ;
Davies, M ;
Hollway, J ;
Aman, MG ;
Cronin, P ;
Koenig, K ;
Kohn, AE ;
McMahon, DJ ;
Tierney, E .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2003, 42 (12) :1443-1450
[7]   Lamotrigine therapy for autistic disorder: A randomized, double-blind, placebo-controlled trial [J].
Belsito, KM ;
Law, PA ;
Kirk, KS ;
Landa, RJ ;
Zimmerman, AW .
JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 2001, 31 (02) :175-181
[8]  
BENT S, 2010, J AUTISM DE IN PRESS
[9]   Early pharmacological treatment of autism: A rationale for developmental treatment [J].
Bethea, Terrence C. ;
Sikich, Linmarie .
BIOLOGICAL PSYCHIATRY, 2007, 61 (04) :521-537
[10]   Fluoxetine but not risperidone increases sociability in the BTBR mouse model of autism [J].
Chadman, Kathryn K. .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2011, 97 (03) :586-594